NASH epidemiology
Oct 09, 2024
Advances in NASH Therapeutics Space: Latest Breakthroughs in Drug Development
Nonalcoholic steatohepatitis (NASH), also referred to as Metabolic Dysfunction-Associated Steatohepatitis (MASH), has rapidly become a significant contributor to liver disease in the United States. The NASH market is growing at a substantial rate, driven by the increasing prevalence of the condition. According to t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
